Skip to main content

Duetact FDA Approval History

FDA Approved: Yes (First approved July 31, 2006)
Brand name: Duetact
Generic name: pioglitazone HCl and glimepiride
Dosage form: Tablets
Company: Takeda Pharmaceuticals North America, Inc.
Treatment for: Diabetes, Type 2

Duetact is a combination of pioglitazone, which directly targets insulin resistance, and glimepiride, a sulfonylurea that acts primarily by increasing the amount of insulin produced by the pancreas. Duetact is indicated for the treatment of type 2 diabetes.

Development timeline for Duetact

Jul 31, 2006Approval Duetact Takeda Pharmaceuticals North America, Inc. - Treatment for Type 2 Diabetes
Jun 30, 2005Takeda Submits New Drug Application for Combination Type 2 Diabetes Medication Containing Pioglitazone HCl and Glimepiride

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.